<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Roh TH</submitter><funding>Ministry of Science and ICT</funding><funding>Yonsei University College of Medicine</funding><funding>Soonchunhyang University</funding><funding>National Research Foundation of Korea</funding><pagination>739-749</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10765002</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>38(6)</volume><pubmed_abstract>&lt;h4>Backgruound&lt;/h4>Phospholipase C-γ (PLC-γ) plays a crucial role in immune responses and is related to the pathogenesis of various inflammatory disorders. In this study, we investigated the role of PLC-γ and the therapeutic effect of the PLC-specific inhibitor U73122 using orbital fibroblasts from patients with Graves' orbitopathy (GO).&lt;h4>Methods&lt;/h4>The expression of phospholipase C gamma 1 (PLCG1) and phospholipase C gamma 2 (PLCG2) was evaluated using polymerase chain reaction in GO and normal orbital tissues/fibroblasts. The primary cultures of orbital fibroblasts were treated with non-toxic concentrations of U73122 with or without interleukin (IL)-1β to determine its therapeutic efficacy. The proinflammatory cytokine levels and activation of downstream signaling molecules were dete</pubmed_abstract><journal>Endocrinology and metabolism (Seoul, Korea)</journal><pubmed_title>Phospholipase C-γ as a Potential Therapeutic Target for Graves' Orbitopathy.</pubmed_title><pmcid>PMC10765002</pmcid><funding_grant_id>2021R1F1A1046652</funding_grant_id><pubmed_authors>Roh TH</pubmed_authors><pubmed_authors>Kikkawa DO</pubmed_authors><pubmed_authors>Ko JS</pubmed_authors><pubmed_authors>Jang SY</pubmed_authors><pubmed_authors>Yoon JS</pubmed_authors><pubmed_authors>Chae MK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Phospholipase C-γ as a Potential Therapeutic Target for Graves' Orbitopathy.</name><description>&lt;h4>Backgruound&lt;/h4>Phospholipase C-γ (PLC-γ) plays a crucial role in immune responses and is related to the pathogenesis of various inflammatory disorders. In this study, we investigated the role of PLC-γ and the therapeutic effect of the PLC-specific inhibitor U73122 using orbital fibroblasts from patients with Graves' orbitopathy (GO).&lt;h4>Methods&lt;/h4>The expression of phospholipase C gamma 1 (PLCG1) and phospholipase C gamma 2 (PLCG2) was evaluated using polymerase chain reaction in GO and normal orbital tissues/fibroblasts. The primary cultures of orbital fibroblasts were treated with non-toxic concentrations of U73122 with or without interleukin (IL)-1β to determine its therapeutic efficacy. The proinflammatory cytokine levels and activation of downstream signaling molecules were dete</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Dec</publication><modification>2026-07-14T21:23:37.869Z</modification><creation>2025-02-19T01:21:02.148Z</creation></dates><accession>S-EPMC10765002</accession><cross_references><pubmed>37989267</pubmed><doi>10.3803/EnM.2023.1780</doi></cross_references></HashMap>